Targets › TREM2
1 program from 1 company in 1 trial: 1 Phase 2; Respiratory.
Forms a receptor signaling complex with TYROBP which mediates signaling and cell activation following ligand binding. Acts as a receptor for amyloid-beta protein 42, a cleavage product of the amyloid-beta precursor protein APP, and mediates its uptake and degradation by microglia. (UniProt, Q9NZC2)
Open in Phaseline: the race on TREM2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| aTyr Pharma | efzofitimod TREM2 agonist | TREM2 | Phase 2 | Interstitial Lung Disease | – |
Interstitial Lung Disease (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.